Barclays PLC Chimerix Inc Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Chimerix Inc stock. As of the latest transaction made, Barclays PLC holds 2,500 shares of CMRX stock, worth $2,200. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,500

Previous 2,500 -0.0%

Holding current value

$2,200

Previous $2,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.87 - $1.05 $282,624 - $341,098	-324,856 Reduced 99.24%	2,500 $2,000
Q1 2024 May 15, 2024	SELL	$0.91 - $1.26 $513,562 - $711,086	-564,354 Reduced 63.29%	327,356 $347,000
Q4 2023 Feb 15, 2024	BUY	$0.9 - $1.06 $51,449 - $60,595	57,166 Added 6.85%	891,710 $858,000
Q2 2023 Aug 03, 2023	SELL	$1.1 - $1.54 $46,957 - $65,741	-42,689 Reduced 4.87%	834,544 $1.01 Million
Q1 2023 May 04, 2023	BUY	$1.19 - $2.09 $237,108 - $416,434	199,251 Added 29.39%	877,233 $1.11 Million
Q4 2022 Feb 13, 2023	BUY	$1.67 - $2.35 $419,383 - $590,150	251,128 Added 58.83%	677,982 $1.26 Million
Q3 2022 Nov 03, 2022	BUY	$1.81 - $2.76 $757,483 - $1.16 Million	418,499 Added 5008.96%	426,854 $825,000
Q2 2022 Aug 12, 2022	SELL	$1.34 - $5.34 $5,142 - $20,494	-3,838 Reduced 31.48%	8,355 $17,000
Q1 2022 May 16, 2022	SELL	$4.58 - $6.8 $349,971 - $519,608	-76,413 Reduced 86.24%	12,193 $56,000
Q4 2021 Feb 14, 2022	BUY	$5.23 - $7.18 $305,039 - $418,773	58,325 Added 192.61%	88,606 $570,000
Q3 2021 Nov 09, 2021	BUY	$5.94 - $8.75 $121,912 - $179,585	20,524 Added 210.35%	30,281 $188,000
Q2 2021 Aug 13, 2021	SELL	$7.54 - $9.79 $302,866 - $393,244	-40,168 Reduced 80.46%	9,757 $79,000
Q1 2021 May 13, 2021	BUY	$4.76 - $11.25 $162,435 - $383,906	34,125 Added 215.98%	49,925 $480,000
Q4 2020 Feb 11, 2021	SELL	$2.43 - $5.42 $15,464 - $34,492	-6,364 Reduced 28.71%	15,800 $77,000
Q3 2020 Nov 12, 2020	SELL	$2.3 - $3.72 $24,225 - $39,182	-10,533 Reduced 32.21%	22,164 $55,000
Q2 2020 Aug 12, 2020	BUY	$1.33 - $3.63 $22,270 - $60,784	16,745 Added 104.97%	32,697 $101,000
Q1 2020 May 13, 2020	SELL	$1.27 - $2.33 $41,803 - $76,694	-32,916 Reduced 67.36%	15,952 $23,000
Q4 2019 Feb 10, 2020	BUY	$1.3 - $2.72 $31,816 - $66,569	24,474 Added 100.33%	48,868 $99,000
Q3 2019 Nov 14, 2019	SELL	$1.93 - $4.21 $14,525 - $31,684	-7,526 Reduced 23.58%	24,394 $58,000
Q2 2019 Aug 14, 2019	BUY	$2.05 - $4.32 $36,004 - $75,872	17,563 Added 122.33%	31,920 $138,000
Q1 2019 May 15, 2019	BUY	$1.79 - $3.12 $23,073 - $40,216	12,890 Added 878.66%	14,357 $30,000
Q4 2018 Feb 14, 2019	SELL	$2.24 - $3.9 $61,906 - $107,784	-27,637 Reduced 94.96%	1,467 $3,000
Q3 2018 Nov 14, 2018	BUY	$3.58 - $4.9 $90,430 - $123,774	25,260 Added 657.13%	29,104 $112,000
Q2 2018 Aug 14, 2018	SELL	$4.43 - $5.14 $29,472 - $34,196	-6,653 Reduced 63.38%	3,844 $18,000
Q1 2018 May 15, 2018	BUY	$4.65 - $5.9 $14,442 - $18,325	3,106 Added 42.02%	10,497 $55,000
Q4 2017 Feb 14, 2018	SELL	$4.32 - $5.52 $234,100 - $299,128	-54,190 Reduced 88.0%	7,391 $34,000
Q3 2017 Nov 14, 2017	BUY	$4.35 - $5.25 $267,877 - $323,300	61,581	61,581 $324,000

Others Institutions Holding CMRX

# of Institutions

Shares Held

37M

Call Options Held

52.7K

Put Options Held

130K

View Full List

About CHIMERIX INC

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $77.1M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

More about CMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account